Summit Therapeutics saw its shares jump following an announcement from AstraZeneca regarding a licensing deal for ivonescimab, Summit's experimental lung cancer drug. AstraZeneca will make an upfront payment of $2 billion, with the total value of the deal potentially reaching $15 billion through various milestone payments.
The agreement grants AstraZeneca a license to manufacture and commercialize ivonescimab for lung cancer treatment. This deal represents a significant financial injection for Summit, which has been operating with substantial quarterly losses. For instance, in Q2 2026, Summit reported a GAAP net loss of $215.7 million, driven by high R&D and G&A expenses, and its operating cash flow consumed $263.4 million over the first half of 2026.
Summit's market capitalization has been volatile, reaching over $23 billion recently, despite generating no revenue in the trailing 12 months. The excitement around ivonescimab stems from strong clinical trial results in China, where it showed a 27% lower mortality risk compared to Keytruda in high PD-L1 lung cancer patients. The drug is a bispecific antibody targeting PD-1 and VEGF receptors.
This partnership follows a period of intense activity for Summit, including two equity offerings in June and July 2026 to manage its cash burn. The company is also awaiting a crucial FDA decision on November 14, 2026, for a narrow indication of ivonescimab in EGFR-mutated non-squamous NSCLC. This deal could provide the necessary capital to sustain development and commercialization efforts, potentially transforming Summit's financial outlook.
Analysts have noted the high valuation of Summit Therapeutics, with its market cap hovering around $14 billion to $20 billion, considering it has no approved products in the U.S. and significant cash burn. The AstraZeneca deal, particularly the substantial upfront payment, helps de-risk Summit's financial position and validates the potential of ivonescimab in the competitive lung cancer treatment landscape.
